EZH2 and small cell lung carcinoma: With the development of molecular biology, several candidate therapeutic targets for SCLC have been reported including poly ADP-ribose polymerase (PARP), enhancer of zeste homologue 2 (EZH2), and delta-like ligand 3 (DLL3).